Has Jorge Betancourt, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,533 in general payments to Jorge Betancourt, MD across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jorge Betancourt, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jorge Betancourt, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jorge Betancourt, MD

Psychiatry · Mia, FLNPI 1982707998

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.9% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,100 and has fallen 98.2% since, to $19 in 2025.

$2,533in general payments, 2019–2025

Across 57 payments — averaging $44.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$385
Otsuka America Pharmaceutical, Inc.$376
Teva Pharmaceuticals USA, Inc.$247
Bard Peripheral Vascular, Inc.$237
E.r. Squibb & Sons, L.L.C.$203
Neurocrine Biosciences, Inc.$177
plus $909 from 9 others

$1,763,353in research payments, 2019–2025

Across 149 payments — averaging $11,835 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$791K
Janssen Research & Development, LLC$505K
Acadia Pharmaceuticals Inc$438K
Alkermes, Inc.$25K
Otsuka Pharmaceutical Development & Commercialization, Inc.$4K

What the payments were for

Food & beverage$2,35393%
Education$1807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	11	$385
Otsuka America Pharmaceutical, Inc.	10	$376
Teva Pharmaceuticals USA, Inc.	7	$247
Bard Peripheral Vascular, Inc.	5	$237
E.r. Squibb & Sons, L.L.C.	2	$203
Neurocrine Biosciences, Inc.	3	$177
Boston Scientific	2	$161
Johnson & Johnson	3	$160
Siemens Medical Solutions USA, Inc.	2	$156
Eisai Inc.	1	$125
Acadia Pharmaceuticals Inc	1	$123
Lundbeck LLC	5	$90
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$37
Idorsia Pharmaceuticals US Inc	2	$36
AbbVie	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,533 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida →

Medicare billing

Part B allowed, 2024

$2,378,817

Medicare patients

329

Services billed

12,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Chlorpromazine Hcl	48	$6,950
Quetiapine Fumarate	82	$1,749
Oxcarbazepine	49	$1,042
Haloperidol	31	$1,009
Memantine Hcl	32	$641
Divalproex Sodium	19	$534
Mirtazapine	65	$425
Trazodone Hcl	82	$408
Temazepam	47	$405
Olanzapine	18	$390
Buspirone Hcl	124	$322
Clonazepam	96	$321
Donepezil Hcl	23	$307
Gabapentin	61	$306
Duloxetine Hcl	14	$300

Paid to pharmacies, not to this prescriber.

Other psychiatry in Mia

Andrew CutlerLakewood Ranch$5.7M
Richard JacksonBoca Raton$3.6M
Ilan MelnickCoral Gables$2.8M
Todd BroderSt Augustine$1.6M
Heather LuingSaint Augustine$1.5M
Todd GatesWest Melbourne$1.2M
Lawrence ReccoppaGainesville$968K
Thomas ValenteLeesburg$967K
Michelle ScargleClearwater$926K
David SheehanTampa$631K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →